Biolinerx Stock Debt To Equity

BLRX Stock

USD 0.27 0.01 3.57%

BioLineRx fundamentals help investors to digest information that contributes to BioLineRx's financial success or failures. It also enables traders to predict the movement of BioLineRx Stock. The fundamental analysis module provides a way to measure BioLineRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLineRx stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.74	0.78

Debt To Equity is likely to rise to 0.78 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioLineRx Company Debt To Equity Analysis

BioLineRx's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current BioLineRx Debt To Equity

0.05 %

Most of BioLineRx's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLineRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioLineRx Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for BioLineRx is extremely important. It helps to project a fair market value of BioLineRx Stock properly, considering its historical fundamentals such as Debt To Equity. Since BioLineRx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioLineRx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioLineRx's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Net Tangible Assets	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.67	0.56	0.79	0.74	0.41	0.74	0.66	0.65	0.65	0.51	-0.74	0.0	0.84	0.61	0.64	0.61	0.08	-0.2	0.69	-0.17	-0.17
Total Stockholder Equity	0.67		-0.19	0.34	0.63	-0.39	0.31	-0.03	0.36	0.05	-0.01	-0.03	-0.05	0.67	-0.09	0.62	0.0	0.66	0.41	0.05	0.45	0.45
Accounts Payable	0.56	-0.19		0.61	0.3	0.94	0.63	0.86	0.51	0.76	0.7	-0.91	0.02	0.36	0.89	0.14	0.76	-0.57	-0.69	0.75	-0.75	-0.75
Long Term Debt	0.79	0.34	0.61		0.41	0.52	0.9	0.67	0.46	0.65	0.58	-0.76	0.19	0.47	0.71	0.28	0.73	-0.02	-0.41	0.71	-0.17	-0.17
Short Term Investments	0.74	0.63	0.3	0.41		0.15	0.25	0.43	0.51	0.49	0.49	-0.47	-0.16	0.94	0.2	0.94	0.15	0.23	0.15	0.45	-0.15	-0.15
Total Liab	0.41	-0.39	0.94	0.52	0.15		0.5	0.88	0.34	0.77	0.66	-0.87	0.03	0.23	0.86	0.04	0.71	-0.67	-0.71	0.76	-0.85	-0.85
Intangible Assets	0.74	0.31	0.63	0.9	0.25	0.5		0.55	0.61	0.43	0.5	-0.75	0.09	0.3	0.77	0.07	0.83	-0.2	-0.62	0.56	-0.09	-0.09
Common Stock	0.66	-0.03	0.86	0.67	0.43	0.88	0.55		0.33	0.96	0.57	-0.93	-0.11	0.56	0.85	0.37	0.69	-0.3	-0.4	0.94	-0.72	-0.72
Property Plant Equipment	0.65	0.36	0.51	0.46	0.51	0.34	0.61	0.33		0.2	0.58	-0.58	-0.14	0.46	0.54	0.33	0.58	-0.32	-0.53	0.3	-0.12	-0.12
Current Deferred Revenue	0.65	0.05	0.76	0.65	0.49	0.77	0.43	0.96	0.2		0.52	-0.83	-0.06	0.63	0.73	0.46	0.56	-0.11	-0.19	0.92	-0.69	-0.69
Net Debt	0.51	-0.01	0.7	0.58	0.49	0.66	0.5	0.57	0.58	0.52		-0.68	0.25	0.37	0.57	0.27	0.45	-0.41	-0.58	0.46	-0.56	-0.56
Retained Earnings	-0.74	-0.03	-0.91	-0.76	-0.47	-0.87	-0.75	-0.93	-0.58	-0.83	-0.68		0.16	-0.54	-0.92	-0.34	-0.83	0.42	0.6	-0.87	0.62	0.62
Net Receivables	0.0	-0.05	0.02	0.19	-0.16	0.03	0.09	-0.11	-0.14	-0.06	0.25	0.16		-0.18	-0.18	-0.22	-0.19	-0.01	-0.09	-0.09	0.04	0.04
Total Current Assets	0.84	0.67	0.36	0.47	0.94	0.23	0.3	0.56	0.46	0.63	0.37	-0.54	-0.18		0.3	0.93	0.25	0.26	0.18	0.6	-0.2	-0.2
Short Term Debt	0.61	-0.09	0.89	0.71	0.2	0.86	0.77	0.85	0.54	0.73	0.57	-0.92	-0.18	0.3		0.04	0.94	-0.51	-0.73	0.78	-0.59	-0.59
Net Tangible Assets	0.64	0.62	0.14	0.28	0.94	0.04	0.07	0.37	0.33	0.46	0.27	-0.34	-0.22	0.93	0.04		0.01	0.34	0.35	0.45	-0.06	-0.06
Short Long Term Debt	0.61	0.0	0.76	0.73	0.15	0.71	0.83	0.69	0.58	0.56	0.45	-0.83	-0.19	0.25	0.94	0.01		-0.5	-0.74	0.7	-0.34	-0.34
Net Invested Capital	0.08	0.66	-0.57	-0.02	0.23	-0.67	-0.2	-0.3	-0.32	-0.11	-0.41	0.42	-0.01	0.26	-0.51	0.34	-0.5		0.86	-0.23	0.52	0.52
Net Working Capital	-0.2	0.41	-0.69	-0.41	0.15	-0.71	-0.62	-0.4	-0.53	-0.19	-0.58	0.6	-0.09	0.18	-0.73	0.35	-0.74	0.86		-0.31	0.44	0.44
Capital Stock	0.69	0.05	0.75	0.71	0.45	0.76	0.56	0.94	0.3	0.92	0.46	-0.87	-0.09	0.6	0.78	0.45	0.7	-0.23	-0.31		-0.5	-0.5
Long Term Debt Total	-0.17	0.45	-0.75	-0.17	-0.15	-0.85	-0.09	-0.72	-0.12	-0.69	-0.56	0.62	0.04	-0.2	-0.59	-0.06	-0.34	0.52	0.44	-0.5		1.0
Capital Surpluse	-0.17	0.45	-0.75	-0.17	-0.15	-0.85	-0.09	-0.72	-0.12	-0.69	-0.56	0.62	0.04	-0.2	-0.59	-0.06	-0.34	0.52	0.44	-0.5	1.0

Click cells to compare fundamentals

BioLineRx Debt To Equity Historical Pattern

Today, most investors in BioLineRx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioLineRx's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioLineRx debt to equity as a starting point in their analysis.

BioLineRx Debt To Equity

Timeline

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict BioLineRx

Debt To Equity Over Time

BioLineRx Total Stockholder Equity

Total Stockholder Equity

12.56 Million

At this time, BioLineRx's Total Stockholder Equity is fairly stable compared to the past year.

According to the company disclosure, BioLineRx has a Debt To Equity of 0.046%. This is 99.91% lower than that of the Biotechnology sector and 99.76% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.91% higher than that of the company.

BioLineRx Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLineRx's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLineRx could also be used in its relative valuation, which is a method of valuing BioLineRx by comparing valuation metrics of similar companies.

BioLineRx is currently under evaluation in debt to equity category among its peers.

BioLineRx Current Valuation Drivers

We derive many important indicators used in calculating different scores of BioLineRx from analyzing BioLineRx's financial statements. These drivers represent accounts that assess BioLineRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioLineRx's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	22.8M	43.3M	92.2M	34.5M	104.2M	68.4M
Enterprise Value	27.9M	34.2M	83.8M	36.3M	111.5M	117.1M

BioLineRx Fundamentals

	Return On Equity	-1.72
	Return On Asset	-0.35
	Profit Margin	(1.77) %
	Operating Margin	(1.07) %
	Current Valuation	25.74 M
	Shares Outstanding	79.94 M
	Shares Owned By Insiders	8.53 %
	Shares Owned By Institutions	3.09 %
	Number Of Shares Shorted	1.06 M
	Price To Earning	(3.88) X
	Price To Book	1.59 X
	Price To Sales	1.30 X
	Revenue	4.8 M
	EBITDA	(57.06 M)
	Net Income	(60.61 M)
	Cash And Equivalents	43.15 M
	Cash Per Share	0.90 X
	Total Debt	11.59 M
	Debt To Equity	0.05 %
	Current Ratio	4.58 X
	Book Value Per Share	0.01 X
	Cash Flow From Operations	(22.61 M)
	Short Ratio	2.39 X
	Earnings Per Share	(0.45) X
	Price To Earnings To Growth	0.20 X
	Target Price	9.83
	Number Of Employees	79
	Beta	0.87
	Market Capitalization	22.23 M
	Total Asset	63.92 M
	Retained Earnings	(390.61 M)
	Working Capital	16.33 M
	Current Asset	48.18 M
	Current Liabilities	3.14 M
	Net Asset	63.92 M

About BioLineRx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioLineRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLineRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLineRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC